{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T07:20:12Z","timestamp":1790061612522,"version":"4.0.1"},"reference-count":166,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This article evaluates and summarizes mechanisms, clinical presentations, comparative assessments, and treatments of cardiotoxicity associated with select classes of anticancer agents, including (1) anthracyclines; (2) arsenic trioxide; (3) HER2-directed therapies; (4) fluoropyrimidines; (5) immunomodulatory drugs (IMiDs); (6) oral kinase inhibitors targeting Bruton\u2019s tyrosine kinase (BTK), the fusion kinase encoded by BCR-ABL1, and the VEGF signaling pathway; and (7) immune checkpoint inhibitors (ICIs). Specific examples of oral kinase inhibitors are also discussed. Together, the evidence highlights and illustrates important breakthroughs and\/or opportunities for pharmacists to advance cardio-oncology pharmacy practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Cardiotoxicity associated with anticancer agents is a common complication in many patients with cancer. The improvement in the life expectancy of patients with cancer has led to a heightened awareness and demand for mitigation strategies in patients at risk of developing long-term anticancer treatment\u2013related adverse effects. Advances in understanding of the pathogenesis associated with drug-induced cardiotoxicity have led to improved surveillance, risk de-escalation for specific therapies (eg, arsenic trioxide), optimization of cardioprotection and harmonization strategies (eg, for anthracyclines), and specific treatment plan modifications or supportive care (eg, for oral kinase inhibitors, fluoropyrimidines, ICIs, and IMiDs), among other approaches. Non\u2013treatment-related factors such as aging, genetic predisposition, and cardiovascular disease contribute to cardiotoxicities; however, some of the mechanisms of drug-induced cardiotoxicity remain poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Strategies to mitigate the cardiotoxicity of anticancer therapies and identify patients who may require time-sensitive interventions or long-term follow-up represent promising opportunities to improve the quality and safety of care in the emerging field of cardio-oncology pharmacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajhp\/zxaf282","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T11:46:10Z","timestamp":1760787970000},"page":"363-380","source":"Crossref","is-referenced-by-count":1,"title":["Rising with cardio-oncology: Clinical considerations of cardiotoxicity with select anticancer drug therapies"],"prefix":"10.1093","volume":"83","author":[{"given":"Clement","family":"Chung","sequence":"first","affiliation":[{"name":"Houston Methodist West Hospital , Houston, TX ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelynn","family":"Tran","sequence":"additional","affiliation":[{"name":"Samaritan Health Services , Corvallis, OR ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,19]]},"reference":[{"issue":"36","key":"2026040814544659100_zxaf282-B1","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"2026040814544659100_zxaf282-B2","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jaccao.2019.09.004","article-title":"Development of a cardio-oncology program in a community hospital","volume":"1","author":"Sundl\u00f6f","year":"2019","journal-title":"JACC CardioOncol"},{"issue":"3","key":"2026040814544659100_zxaf282-B3","first-page":"127","article-title":"Cardio-oncology for the primary care provider","volume":"61","author":"Jhawar","year":"2023","journal-title":"Rom J Intern Med"},{"issue":"17-18","key":"2026040814544659100_zxaf282-B4","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1007\/s00508-022-02031-0","article-title":"Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies: position paper of the Heart Failure Working Group of the Austrian Society of Cardiology","volume":"134","author":"Bergler-Klein","year":"2022","journal-title":"Wien Klin Wochenschr"},{"issue":"2","key":"2026040814544659100_zxaf282-B5","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaccao.2024.09.014","article-title":"Cardiovascular safety in oncology clinical trials: JACC: CardioOncology primer","volume":"7","author":"Bonaca","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"3","key":"2026040814544659100_zxaf282-B6","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncol"},{"issue":"21","key":"2026040814544659100_zxaf282-B7","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.4103\/0366-6999.244101","article-title":"Emergence, development, and future of cardio-oncology in China","volume":"131","author":"Liu","year":"2018","journal-title":"Chin Med J"},{"issue":"16 suppl","key":"2026040814544659100_zxaf282-B8","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1200\/JCO.2025.43.16_suppl.e24025","article-title":"Chimeric antigen receptor T-cell therapy related cardiovascular adverse effects: a National Inpatient Sample study","volume":"43","author":"Park","year":"2025","journal-title":"J Clin Oncol"},{"issue":"41","key":"2026040814544659100_zxaf282-B9","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"ESC guideline on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"issue":"4","key":"2026040814544659100_zxaf282-B10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3904\/kjim.2016.017","article-title":"Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity","volume":"31","author":"Chung","year":"2016","journal-title":"Korean J Intern Med"},{"issue":"1","key":"2026040814544659100_zxaf282-B11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2026040814544659100_zxaf282-B12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ctrv.2003.07.003","article-title":"Cardiotoxicity of cytotoxic drugs","volume":"30","author":"Schimmel","year":"2004","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2026040814544659100_zxaf282-B13","doi-asserted-by":"crossref","first-page":"e000472","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2026040814544659100_zxaf282-B14","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13048-022-01029-6","article-title":"Cardiac safety analysis of first-line chemotherapy drug pegylated liposomal doxorubicin in ovarian cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Ovarian Res"},{"issue":"31","key":"2026040814544659100_zxaf282-B15","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026040814544659100_zxaf282-B16","author":"Morgan"},{"issue":"20","key":"2026040814544659100_zxaf282-B17","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.jacc.2017.09.1095","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 2","volume":"70","author":"Chang","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2026040814544659100_zxaf282-B18","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1038\/bjc.2015.82","article-title":"Incidence and relevance of QTc-interval prolongation caused by tyrosine kinase inhibitors","volume":"112","author":"Kloth","year":"2015","journal-title":"Br J Cancer"},{"key":"2026040814544659100_zxaf282-B19","author":"National Cancer Institute"},{"issue":"18","key":"2026040814544659100_zxaf282-B20","doi-asserted-by":"crossref","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"2026040814544659100_zxaf282-B21","author":"Makielski"},{"issue":"2","key":"2026040814544659100_zxaf282-B22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1573403X12666160301120217","article-title":"Drug-induced inhibition and trafficking disruption of ion channels: pathogenesis of QT abnormalities and drug-induced fatal arrhythmias","volume":"12","author":"Cubeddu","year":"2016","journal-title":"Curr Cardiol Rev"},{"issue":"2","key":"2026040814544659100_zxaf282-B23","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.hrthm.2004.03.061","article-title":"Role of sodium and calcium channel block in unmasking the Brugada syndrome","volume":"1","author":"Fish","year":"2004","journal-title":"Heart Rhythm"},{"issue":"11","key":"2026040814544659100_zxaf282-B24","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"2026040814544659100_zxaf282-B25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jaccao.2020.03.002","article-title":"Cardiotoxicity surveillance and risk of heart failure during HER2 targeted therapy","volume":"2","author":"Yu","year":"2020","journal-title":"JACC CardioOncol"},{"key":"2026040814544659100_zxaf282-B26","first-page":"1","article-title":"Ham-Wasserman lecture: treatment of acute leukemia by inducing differentiation and apoptosis","author":"Wang","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"2026040814544659100_zxaf282-B27","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12012-018-09504-7","article-title":"An overview on arsenic trioxide-induced cardiotoxicity","volume":"19","author":"Vineetha","year":"2019","journal-title":"Cardiovasc Toxicol"},{"issue":"3","key":"2026040814544659100_zxaf282-B28","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.etap.2015.08.030","article-title":"Arsenic cardiotoxicity: an overview","volume":"40","author":"Alamolhodaei","year":"2015","journal-title":"Environ Toxicol Pharmacol"},{"key":"2026040814544659100_zxaf282-B29","author":"Trisenox (arsenic trioxide)"},{"key":"2026040814544659100_zxaf282-B30"},{"issue":"15","key":"2026040814544659100_zxaf282-B31","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1182\/blood-2019-01-894980","article-title":"Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet","volume":"133","author":"Sanz","year":"2019","journal-title":"Blood"},{"issue":"33","key":"2026040814544659100_zxaf282-B32","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1200\/JCO.2013.51.2913","article-title":"Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide","volume":"32","author":"Roboz","year":"2014","journal-title":"J Clin Oncol"},{"issue":"16","key":"2026040814544659100_zxaf282-B33","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/ajhp\/zxaf058","article-title":"Therapeutic advances in chronic lymphocytic leukemia: a focus on molecular pathogenesis, targeted therapies, and supportive care","volume":"82","author":"Chung","year":"2025","journal-title":"Am J Health-Syst Pharm"},{"issue":"1","key":"2026040814544659100_zxaf282-B34","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","author":"Lipsky","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"2026040814544659100_zxaf282-B35","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf237","article-title":"Considerations for the practical management of cardiovascular risk with Bruton\u2019s tyrosine kinase inhibitors for patients with CLL","volume":"30","author":"Lenihan","year":"2025","journal-title":"Oncologist"},{"issue":"9","key":"2026040814544659100_zxaf282-B36","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/imj.70159","article-title":"Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton\u2019s tyrosine kinase inhibitors","volume":"55","author":"Anderson","year":"2025","journal-title":"Intern Med J"},{"key":"2026040814544659100_zxaf282-B37"},{"issue":"9","key":"2026040814544659100_zxaf282-B38","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/j.annonc.2024.06.016","article-title":"ESMO clinical practice guideline interim update on new targeted therapies in the first line and at relapse of chronic lymphocytic leukaemia","volume":"35","author":"Eichhorst","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"2026040814544659100_zxaf282-B39","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1248\/bpb.b12-00778","article-title":"Blocking of the human ether-\u00e0-go-go-related gene channel by imatinib mesylate","volume":"36","author":"Dong","year":"2013","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"2026040814544659100_zxaf282-B40","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1182\/blood-2018-01-821629","article-title":"Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2026040814544659100_zxaf282-B41","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026040814544659100_zxaf282-B42","doi-asserted-by":"crossref","first-page":"107505","DOI":"10.1016\/j.leukres.2024.107505","article-title":"A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed\/refractory acute myeloid leukemia","volume":"141","author":"Mohebbi","year":"2024","journal-title":"Leuk Res"},{"key":"2026040814544659100_zxaf282-B43","author":"Vanflyta (quizartinib)"},{"key":"2026040814544659100_zxaf282-B44","author":"Tasigna (nilotinib)"},{"issue":"11","key":"2026040814544659100_zxaf282-B45","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"Abu Rmilah","year":"2020","journal-title":"Int J Cancer"},{"issue":"20","key":"2026040814544659100_zxaf282-B46","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/j.jacc.2017.09.1096","article-title":"Cardiovascular complications of cancer therapy: best practices in diagnosis, prevention, and management: part 1","volume":"70","author":"Chang","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2026040814544659100_zxaf282-B47","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/bjc.2014.564","article-title":"QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors","volume":"112","author":"Ghatalia","year":"2015","journal-title":"Br J Cancer"},{"issue":"12","key":"2026040814544659100_zxaf282-B48","doi-asserted-by":"crossref","first-page":"e007724","DOI":"10.1161\/JAHA.117.007724","article-title":"Incidence, diagnosis, and management of QT prolongation induced by cancer therapies: a systematic review","volume":"6","author":"Porta-S\u00e1nchez","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"15","key":"2026040814544659100_zxaf282-B49","doi-asserted-by":"crossref","first-page":"e811","DOI":"10.1161\/CIR.0000000000001056","article-title":"Cardio-oncology drug interactions: a scientific statement from the American Heart Association","volume":"145","author":"Beavers","year":"2022","journal-title":"Circulation"},{"key":"2026040814544659100_zxaf282-B50","author":"Votrient (pazopanib)"},{"key":"2026040814544659100_zxaf282-B51","author":"Kisqali (ribociclib)"},{"key":"2026040814544659100_zxaf282-B52","author":"Daurismo (glasdegib)"},{"key":"2026040814544659100_zxaf282-B53","author":"Sutent (sunitinib)"},{"issue":"23","key":"2026040814544659100_zxaf282-B54","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","article-title":"Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude lifetime cohort study","volume":"65","author":"Armstrong","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2026040814544659100_zxaf282-B55","doi-asserted-by":"crossref","first-page":"736854","DOI":"10.3389\/fcvm.2021.736854","article-title":"Risk factors for anthracycline-induced cardiotoxicity","volume":"8","author":"Qiu","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2026040814544659100_zxaf282-B56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis","volume":"1","author":"Rafiyath","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"2026040814544659100_zxaf282-B57","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1365-2141.2005.05759.x","article-title":"Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies","volume":"131","author":"Wouters","year":"2005","journal-title":"Br J Haematol"},{"issue":"3","key":"2026040814544659100_zxaf282-B58","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/1440-1681.13036","article-title":"Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity","volume":"46","author":"Corremans","year":"2019","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"3","key":"2026040814544659100_zxaf282-B59","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ygyno.2013.03.012","article-title":"Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary?","volume":"129","author":"Gill","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"10","key":"2026040814544659100_zxaf282-B60","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1073\/pnas.85.10.3585","article-title":"Doxorubicin cardiotoxicity may be caused by its metabolite, doxorubicinol","volume":"85","author":"Olson","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2026040814544659100_zxaf282-B61","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCRESAHA.113.300218","article-title":"Emerging paradigms in cardiomyopathies associated with cancer therapies","volume":"113","author":"Ky","year":"2013","journal-title":"Circ Res"},{"issue":"1","key":"2026040814544659100_zxaf282-B62","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jaccao.2022.01.097","article-title":"How to apply translational models to probe mechanisms of cardiotoxicity","volume":"4","author":"Livingston","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026040814544659100_zxaf282-B63","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ejca.2023.02.019","article-title":"Anthracycline-induced cardiotoxicity\u2014are we about to clear this hurdle?","volume":"185","author":"Dempke","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"2026040814544659100_zxaf282-B64","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1159\/000512771","article-title":"Anthracycline-induced cardiotoxicity: the role of endothelial dysfunction","volume":"146","author":"Grakova","year":"2021","journal-title":"Cardiology"},{"issue":"11","key":"2026040814544659100_zxaf282-B65","doi-asserted-by":"crossref","first-page":"e008209","DOI":"10.1161\/CIRCHEARTFAILURE.120.008209","article-title":"Clinically translatable prevention of anthracycline cardiotoxicity by dexrazoxane is mediated by topoisomerase II\u03b2 and not metal chelation","volume":"14","author":"Jirkovsk\u00fd","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"13","key":"2026040814544659100_zxaf282-B66","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.2011.34.8987","article-title":"Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes\u2014a report from the Children\u2019s Oncology Group","volume":"30","author":"Blanco","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2026040814544659100_zxaf282-B67","first-page":"CD014638","article-title":"Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines","volume":"9","author":"de Baat","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"2026040814544659100_zxaf282-B68","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"2026040814544659100_zxaf282-B69","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fcvm.2020.00026","article-title":"Cardiotoxicity of anthracyclines","volume":"7","author":"Cardinale","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"10","key":"2026040814544659100_zxaf282-B70","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of prognostic value of left ventricular global longitudinal strain for early prediction of chemotherapy-induced cardiotoxicity: a systematic review and meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol"},{"issue":"4","key":"2026040814544659100_zxaf282-B71","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jacc.2020.11.020","article-title":"Strain-guided management of potentially cardiotoxic cancer therapy","volume":"77","author":"Thavendiranathan","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026040814544659100_zxaf282-B72","doi-asserted-by":"crossref","first-page":"8863789","DOI":"10.1155\/2021\/8863789","article-title":"Role of oxidative stress in the mechanisms of anthracycline-induced cardiotoxicity: effects of preventive strategies","volume":"2021","author":"Carrasco","year":"2021","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"2026040814544659100_zxaf282-B73","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1542\/peds.2012-0727","article-title":"Continuous versus bolus infusion of doxorubicin in children with ALL: long-term cardiac outcomes","volume":"130","author":"Lipshultz","year":"2012","journal-title":"Pediatrics"},{"issue":"5","key":"2026040814544659100_zxaf282-B74","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/bloodadvances.2020002982","article-title":"Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines","volume":"5","author":"Moccia","year":"2021","journal-title":"Blood Adv"},{"issue":"2","key":"2026040814544659100_zxaf282-B75","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/bjh.14232","article-title":"A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma","volume":"175","author":"Park","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"2026040814544659100_zxaf282-B76","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial","volume":"32","author":"Fields","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026040814544659100_zxaf282-B77","doi-asserted-by":"crossref","first-page":"1448037","DOI":"10.3389\/fcell.2024.1448037","article-title":"Efficacy and safety of pegylated liposomal doxorubicin and epirubicin as neoadjuvant chemotherapy for breast cancer","volume":"12","author":"Shen","year":"2024","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2026040814544659100_zxaf282-B78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/1097-0142(19890101)63:1<37::AID-CNCR2820630106>3.0.CO;2-Z","article-title":"Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma","volume":"63","author":"Hortobagyi","year":"1989","journal-title":"Cancer"},{"issue":"9","key":"2026040814544659100_zxaf282-B79","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.jacc.2014.06.1167","article-title":"Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities","volume":"64","author":"Vejpongsa","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2026040814544659100_zxaf282-B80","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/CIRCRESAHA.113.300218","article-title":"Emerging paradigms in cardiomyopathies associated with cancer therapies","volume":"113","author":"Ky","year":"2013","journal-title":"Circ Res"},{"issue":"2","key":"2026040814544659100_zxaf282-B81","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s10549-012-2103-8","article-title":"Mechanisms of cardiotoxicity associated with ErbB2 inhibitors","volume":"134","author":"Fedele","year":"2012","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"2026040814544659100_zxaf282-B82","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2015.3709","article-title":"Cardiac outcomes of patients receiving adjuvant weekly paclitaxel and trastuzumab for node-negative, ERBB2-positive breast cancer","volume":"2","author":"Dang","year":"2016","journal-title":"JAMA Oncol"},{"issue":"2","key":"2026040814544659100_zxaf282-B83","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1406281","article-title":"Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer","volume":"372","author":"Tolaney","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"2026040814544659100_zxaf282-B84","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12609-017-0249-4","article-title":"Incidence, diagnosis, and treatment of cardiac toxicity from trastuzumab in patients with breast cancer","volume":"9","author":"Nowsheen","year":"2017","journal-title":"Curr Breast Cancer Rep"},{"issue":"1","key":"2026040814544659100_zxaf282-B85","doi-asserted-by":"crossref","first-page":"100772","DOI":"10.1016\/j.esmoop.2022.100772","article-title":"Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial","volume":"8","author":"de Azambuja","year":"2023","journal-title":"ESMO Open"},{"issue":"22","key":"2026040814544659100_zxaf282-B86","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.jacc.2010.11.063","article-title":"The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy","volume":"57","author":"Fallah-Rad","year":"2011","journal-title":"J Am Coll Cardiol"},{"issue":"10191","key":"2026040814544659100_zxaf282-B87","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet"},{"key":"2026040814544659100_zxaf282-B88","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ctrv.2019.02.003","article-title":"Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: a meta-analysis of randomized controlled trials","volume":"75","author":"Chen","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"2026040814544659100_zxaf282-B89","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fonc.2020.00288","article-title":"Six months vs. 12 months of adjuvant trastuzumab among women with HER2-positive early-stage breast cancer: a meta-analysis of randomized controlled trials","volume":"10","author":"Deng","year":"2020","journal-title":"Front Oncol"},{"issue":"12","key":"2026040814544659100_zxaf282-B90","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/S1470-2045(17)30717-9","article-title":"Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"18","author":"Martin","year":"2017","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026040814544659100_zxaf282-B91","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026040814544659100_zxaf282-B92","author":"Herceptin (trastuzumab)"},{"key":"2026040814544659100_zxaf282-B93","author":"Kadcyla (ado-trastuzumab emtansine)"},{"key":"2026040814544659100_zxaf282-B94","author":"Enhertu (fam-trastuzumab deruxtecan)"},{"key":"2026040814544659100_zxaf282-B95","author":"Herceptin Hylecta (trastuzumab and hyaluronidase)"},{"key":"2026040814544659100_zxaf282-B96","author":"Phesgo (pertuzumab, trastuzumab, and hyaluronidase)"},{"key":"2026040814544659100_zxaf282-B97","author":"Tukysa (tucatinib)"},{"key":"2026040814544659100_zxaf282-B98","author":"Tykerb (lapatinib)"},{"key":"2026040814544659100_zxaf282-B99","author":"Nerlynx (neratinib)"},{"issue":"19","key":"2026040814544659100_zxaf282-B100","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.3390\/jcm10194426","article-title":"Cardiotoxicity of fluoropyrimidines: epidemiology, mechanisms, diagnosis, and management","volume":"10","author":"Jurczyk","year":"2021","journal-title":"J Clin Med"},{"issue":"suppl 1","key":"2026040814544659100_zxaf282-B101","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.2459\/JCM.0000000000000376","article-title":"Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy","volume":"17","author":"Madeddu","year":"2016","journal-title":"J Cardiovasc Med"},{"issue":"4","key":"2026040814544659100_zxaf282-B102","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00280-005-0178-1","article-title":"Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine","volume":"58","author":"Jensen","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2026040814544659100_zxaf282-B103","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.30321","article-title":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","volume":"123","author":"Ma","year":"2017","journal-title":"Cancer"},{"key":"2026040814544659100_zxaf282-B104","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.002","article-title":"Fluoropyrimidine-induced cardiotoxicity","volume":"124","author":"Depetris","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"2026040814544659100_zxaf282-B105","first-page":"399","article-title":"Fluoropyrimidine-associated cardiotoxicity","volume":"37","author":"Kanduri","year":"2019","journal-title":"Cardiol Clin"},{"issue":"4","key":"2026040814544659100_zxaf282-B106","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jaccao.2025.01.019","article-title":"Fluoropyrimidine chemotherapy and the risk of death and cardiovascular events in patients with gastrointestinal cancer","volume":"7","author":"Abiodun","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"6","key":"2026040814544659100_zxaf282-B107","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11912-016-0521-1","article-title":"Fluoropyrimidine-induced cardiotoxicity: manifestations, mechanisms, and management","volume":"18","author":"Layoun","year":"2016","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"2026040814544659100_zxaf282-B108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ehjcr\/ytz146","article-title":"Fluorouracil-induced Takotsubo cardiomyopathy causing cardiogenic shock: a case report of clinical and acute cardiac magnetic resonance imaging features","volume":"3","author":"Joy","year":"2019","journal-title":"Eur Heart J Case Rep"},{"issue":"3","key":"2026040814544659100_zxaf282-B109","first-page":"e14049","article-title":"5-Fluorouracil induced Takotsubo cardiomyopathy complicated by left ventricular thrombosis","volume":"13","author":"Kumar","year":"2021","journal-title":"Cureus"},{"issue":"4","key":"2026040814544659100_zxaf282-B110","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.jaccao.2020.06.012","article-title":"How to diagnose and manage patients with fluoropyrimidine-induced chest pain: a single center approach","volume":"2","author":"Padegimas","year":"2020","journal-title":"JACC CardioOncol"},{"issue":"5","key":"2026040814544659100_zxaf282-B111","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.21037\/jgo.2019.07.04","article-title":"Successful 5-fluorouracil (5-FU) infusion re-challenge in a metastatic colorectal cancer patient with coronary artery disease who experienced symptoms consistent with coronary vasospasm during first 5-FU infusion","volume":"10","author":"Redman","year":"2019","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"2026040814544659100_zxaf282-B112","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1365-2796.2003.01297.x","article-title":"Manipulating angiogenesis in medicine","volume":"255","author":"Carmeliet","year":"2004","journal-title":"J Intern Med"},{"issue":"6","key":"2026040814544659100_zxaf282-B113","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jash.2018.03.008","article-title":"Vascular toxicities with VEGF inhibitor therapies\u2014focus on hypertension and arterial thrombotic events","volume":"12","author":"Touyz","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"2026040814544659100_zxaf282-B114","doi-asserted-by":"crossref","first-page":"3695","DOI":"10.2147\/OTT.S103735","article-title":"Risk of venous and arterial thromboembolic events associated with anti-VEGF agents in advanced non-small-cell lung cancer: a meta-analysis and systematic review","volume":"9","author":"Zhang","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"2","key":"2026040814544659100_zxaf282-B115","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (vascular endothelial growth factor) inhibitor-associated hypertension and vascular disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"issue":"9544","key":"2026040814544659100_zxaf282-B116","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"2026040814544659100_zxaf282-B117","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"2026040814544659100_zxaf282-B118","author":"Choueiri"},{"issue":"4","key":"2026040814544659100_zxaf282-B119","first-page":"309","article-title":"Cardiotoxicity of anticancer treatments: epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2026040814544659100_zxaf282-B120","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00280-012-2025-5","article-title":"Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis","volume":"71","author":"Qi","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"issue":"9","key":"2026040814544659100_zxaf282-B121","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"2026040814544659100_zxaf282-B122","author":"Inlyta (axitinib)"},{"key":"2026040814544659100_zxaf282-B123","author":"Cabometyx (cabozantinib)"},{"key":"2026040814544659100_zxaf282-B124","author":"Fruzaqla (fruquintinib)"},{"key":"2026040814544659100_zxaf282-B125","author":"Lenvima (lenvatinib)"},{"issue":"7","key":"2026040814544659100_zxaf282-B126","doi-asserted-by":"crossref","first-page":"e101145","DOI":"10.1371\/journal.pone.0101145","article-title":"Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer","volume":"9","author":"Faruque","year":"2014","journal-title":"PLoS One"},{"key":"2026040814544659100_zxaf282-B127","author":"Stivarga (regorafenib)"},{"key":"2026040814544659100_zxaf282-B128","author":"Nexavar (sorafenib)"},{"key":"2026040814544659100_zxaf282-B129","author":"Fotivda (tivozanib)"},{"issue":"5","key":"2026040814544659100_zxaf282-B130","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"issue":"3","key":"2026040814544659100_zxaf282-B131","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jaccao.2025.01.020","article-title":"Immune checkpoint inhibitor myocarditis and left ventricular systolic dysfunction","volume":"7","author":"Chen","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"11","key":"2026040814544659100_zxaf282-B132","doi-asserted-by":"crossref","first-page":"e007405","DOI":"10.1161\/CIRCHEARTFAILURE.120.007405","article-title":"Management of acute myocarditis and chronic inflammatory cardiomyopathy: an expert consensus document","volume":"13","author":"Ammirati","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"10","key":"2026040814544659100_zxaf282-B133","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/jcpt.13707","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"47","author":"Wang","year":"2022","journal-title":"J Clin Pharm Ther"},{"key":"2026040814544659100_zxaf282-B134","doi-asserted-by":"crossref","first-page":"104398","DOI":"10.1016\/j.critrevonc.2024.104398","article-title":"Safety of immune checkpoint inhibitors: an updated comprehensive disproportionality analysis and meta-analysis","volume":"200","author":"Tyagi","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10124","key":"2026040814544659100_zxaf282-B135","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"2026040814544659100_zxaf282-B136","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"7","key":"2026040814544659100_zxaf282-B137","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","article-title":"Cardiotoxicity of immune checkpoint inhibitors","volume":"23","author":"Patel","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"8","key":"2026040814544659100_zxaf282-B138","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2026040814544659100_zxaf282-B139","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1001\/jamaoncol.2015.5932","article-title":"Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis","volume":"2","author":"Douxfils","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"2026040814544659100_zxaf282-B140","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/cam4.1019","article-title":"Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA-ROCK pathway","volume":"6","author":"Dasgupta","year":"2017","journal-title":"Cancer Med"},{"issue":"6","key":"2026040814544659100_zxaf282-B141","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ejca.2007.01.018","article-title":"Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005","volume":"43","author":"Verweij","year":"2007","journal-title":"Eur J Cancer"},{"key":"2026040814544659100_zxaf282-B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.06.007","article-title":"Cardiovascular disease in patients with chronic myeloid leukemia: JACC: CardioOncology state-of-the-art review","author":"Aghel","year":"13, 2025","journal-title":"JACC CardioOncol"},{"issue":"16 suppl","key":"2026040814544659100_zxaf282-B143","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1200\/JCO.2024.42.16_suppl.6563","article-title":"Cardiovascular complications associated with asciminib use: a retrospective analysis","volume":"42","author":"Savani","year":"2024","journal-title":"J Clin Ocol"},{"key":"2026040814544659100_zxaf282-B144","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.leukres.2016.07.007","article-title":"Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients","volume":"48","author":"Dorer","year":"2016","journal-title":"Leuk Res"},{"issue":"4","key":"2026040814544659100_zxaf282-B145","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2026040814544659100_zxaf282-B146","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1159\/000501927","article-title":"Ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute leukemia: recommendations of a German expert consensus panel with focus on cardiovascular management","volume":"143","author":"Saussele","year":"2020","journal-title":"Acta Haematol"},{"issue":"1","key":"2026040814544659100_zxaf282-B147","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1182\/asheducation-2017.1.110","article-title":"Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy","author":"Barber","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2026040814544659100_zxaf282-B148","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1002\/cncr.32682","article-title":"Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis","volume":"126","author":"Chakraborty","year":"2020","journal-title":"Cancer"},{"issue":"8","key":"2026040814544659100_zxaf282-B149","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/jth.15758","article-title":"Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: lessons from the substudy of IFM\/DFCI 2009 cohort","volume":"20","author":"Chalayer","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"21","key":"2026040814544659100_zxaf282-B150","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"21","key":"2026040814544659100_zxaf282-B151","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2026040814544659100_zxaf282-B152","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"key":"2026040814544659100_zxaf282-B153"},{"issue":"16","key":"2026040814544659100_zxaf282-B154","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2026040814544659100_zxaf282-B155","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.chest.2024.03.003","article-title":"Antithrombotic therapy for VTE disease: compendium and review of CHEST guidelines 2012-2021","volume":"166","author":"Stevens","year":"2024","journal-title":"Chest"},{"issue":"1","key":"2026040814544659100_zxaf282-B156","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaccao.2022.02.001","article-title":"Redefining heart failure in breast cancer","volume":"4","author":"Volgman","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026040814544659100_zxaf282-B157","author":"Floyd"},{"key":"2026040814544659100_zxaf282-B158","doi-asserted-by":"crossref","first-page":"1372817","DOI":"10.3389\/fcvm.2024.1372817","article-title":"Anticancer drugs and cardiotoxicity: the role of cardiomyocyte and non-cardiomyocyte cells","volume":"11","author":"Koukorava","year":"2024","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"2026040814544659100_zxaf282-B159","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10741-017-9653-0","article-title":"Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients","volume":"23","author":"Ruggeri","year":"2018","journal-title":"Heart Fail Rev"},{"issue":"22","key":"2026040814544659100_zxaf282-B160","doi-asserted-by":"crossref","first-page":"11910","DOI":"10.3390\/ijms252211910","article-title":"Transforming cardiotoxicity detection in cancer therapies: the promise of microRNAs as precision biomarkers","volume":"25","author":"Moscoso","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2026040814544659100_zxaf282-B161","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jaccao.2024.07.012","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes for preclinical cardiotoxicity screening in cardio-oncology","volume":"6","author":"Shead","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"377","key":"2026040814544659100_zxaf282-B162","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf2584","article-title":"High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells","volume":"9","author":"Sharma","year":"2017","journal-title":"Sci Transl Med"},{"issue":"5","key":"2026040814544659100_zxaf282-B163","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat Med"},{"issue":"8","key":"2026040814544659100_zxaf282-B164","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1177\/10781552221145667","article-title":"Exploration of current pharmacy practice in cardio-oncology: experiences & perspectives","volume":"29","author":"Merali","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"1","key":"2026040814544659100_zxaf282-B165","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jaccao.2022.12.001","article-title":"Cardio-oncology guidelines and strength of the evidence","volume":"5","author":"Zheng","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"9","key":"2026040814544659100_zxaf282-B166","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/ajhp\/zxz036","article-title":"Instilling value, quality, and safety through hematology and oncology stewardship","volume":"76","author":"Chung","year":"2019","journal-title":"Am J Health-Syst Pharm"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxaf282\/64818018\/zxaf282.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/8\/363\/64818018\/zxaf282.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/83\/8\/363\/64818018\/zxaf282.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T18:55:07Z","timestamp":1775674507000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/83\/8\/363\/8293140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,19]]},"references-count":166,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,10,19]]},"published-print":{"date-parts":[[2026,4,7]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxaf282","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4,15]]},"published":{"date-parts":[[2025,10,19]]}}}